Publications by authors named "D Pascual-Figal"
Introduction Y Objectives: Tako-tsubo syndrome (TTS) is a cardiac condition that mimics acute coronary syndrome, characterized by transient left ventricular dysfunction in the absence of culprit coronary artery stenosis. Although its etiology remains unknown, reversible microvascular dysfunction secondary to an adrenergic surge is thought to play a role. Treatment is empirical, although most patients receive beta-blockers (BB) in clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- Heart failure with preserved ejection fraction (HFpEF) is a complex health issue influenced by various comorbidities, making it difficult to tailor treatments based on individual pathology.
- A study using mouse models over 2.5 years revealed that different comorbidities like aging, obesity, hypertension, chronic intermittent hypoxia, and hyperglycemia each contribute uniquely to HFpEF through various mechanisms leading to cardiac and non-cardiac changes.
- The research emphasized that understanding the specific characteristics of these contributions can help clarify HFpEF progression and align with patterns seen in human patients, potentially guiding future therapeutic strategies.
Article Synopsis
- Guidelines suggest low-dose colchicine can help prevent secondary cardiovascular issues, but its effectiveness for stroke and safety risks are still uncertain.
- A meta-analysis of six trials with nearly 15,000 patients showed colchicine reduces the risk of ischaemic stroke and major cardiovascular events by 27% without increasing serious safety concerns.
- Colchicine's benefits were consistent across different patient groups, and it didn't raise the risk of hospitalization for serious conditions or all-cause mortality.
Article Synopsis
- Transthyretin cardiac amyloidosis (ATTR-CA) is a treatable form of heart failure, often associated with atrial fibrillation (AF), and the study explores if recent-onset AF can indicate ATTR-CA in patients over 65.
- In a study of 121 patients recently diagnosed with nonvalvular AF, 10 were found to have cardiac amyloidosis, with notable differences in age, sex, and heart metrics observed between those with and without the condition.
- The findings suggest that routine screening for ATTR-CA using echocardiography and other tests may benefit older patients with AF and specific heart features, although more extensive research is needed to confirm these results in varied clinical situations.
Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review.
Front Cardiovasc Med
September 2024
Article Synopsis
- The main goals of treating heart failure with reduced ejection fraction (HFrEF) are to lower mortality rates and reduce hospitalizations, while also improving the overall quality of life and cardiac function for patients.
- Effective treatments such as RAS inhibitors (ACE inhibitors, ARBs, ARNIs), beta-blockers, and SGLT2 inhibitors have shown benefits in reducing mortality, hospitalization, and the risk of sudden death, as well as aiding in cardiac remodeling and renal protection.
- The ideal HFrEF treatment should be effective across various patient profiles, taking into account individual differences and comorbidities, while maximizing overall health benefits beyond just heart function.